Q2 2026 · Form 13F Ledger數據來源:SEC EDGAR  
H

HOLDER.TOP

誰持有什麼——美股機構持倉的季度賬本。
EN · 简 · 繁
機構 / Affinity Asset Advisors, LLC
Form 13F · Q2 2026

Affinity Asset Advisors, LLC

CIK 1773195申報日 2026-08-1313F-HR 在 EDGAR 查看原始申報 ↗
$22.1亿
申報組合市值
113
持倉數量
12
Quarters on record
Top 50
持倉數量

Affinity Asset Advisors, LLC——持倉

共 113 個持倉中的前 50 名,按申報市值排名。股數變動與上一季度對比。
#證券股數股數環比市值佔其組合
1ROIV Roivant Sciences Ltd3.8M+33.9%$1.3亿6.0%
2APOGEE THERAPEUTICS INC Apogee Therapeutics Inc987,000−23.2%$1.3亿5.9%
3SYRE Spyre Therapeutics Inc1.3M+0.0%$1.1亿5.1%
4XENE Xenon Pharmaceuticals Inc1.6M−4.8%$9627万4.4%
5ERAS Erasca Inc5.2M−1.9%$9618万4.3%
6INSM Insmed Inc650,000+35.4%$6930万3.1%
7PRAX Praxis Precision Medicines I185,000+8.8%$6194万2.8%
8ALKS Alkermes Plc1.1M−16.7%$5894万2.7%
9ORKA Oruka Therapeutics Inc590,000+18.1%$5615万2.5%
10ANAB Anaptysbio Inc826,109−12.1%$5576万2.5%
11AVTX Avalo Therapeutics Inc2.9M+116.3%$5359万2.4%
12CYTK Cytokinetics Inc550,000−21.5%$4685万2.1%
13RVMD Revolution Medicines Inc250,000+150.0%$4682万2.1%
14ABVX Abivax Sa330,000−18.5%$4398万2.0%
15TRAX First Tracks Biotherapeutics2.0M—$4088万1.8%
16DNTH Dianthus Therapeutics Inc400,000+14.3%$3899万1.8%
17STRO Sutro Biopharma Inc1.2M+9.6%$3893万1.8%
18NUVALENT INC Nuvalent Inc275,000−8.3%$3396万1.5%
19TRVI Trevi Therapeutics Inc1.8M−10.0%$3357万1.5%
20OVID Ovid Therapeutics Inc10.1M−4.6%$2729万1.2%
21LXEO Lexeo Therapeutics Inc5.8M+15.0%$2703万1.2%
22CLDX Celldex Therapeutics Inc New700,000+40.0%$2605万1.2%
23BLTE Belite Bio Inc165,000+153.8%$2541万1.1%
24ELVN Enliven Therapeutics Inc500,000−14.8%$2538万1.1%
25FORTE BIOSCIENCES INC Forte Biosciences Inc1.1M+13.2%$2434万1.1%
26NRIX Nurix Therapeutics Inc967,620+0.0%$2347万1.1%
27ANRO Alto Neuroscience Inc850,000+70.0%$2243万1.0%
28MDGL Madrigal Pharmaceuticals Inc40,000−27.3%$2148万1.0%
29PTGX Protagonist Therapeutics Inc172,125+0.0%$2110万1.0%
30MLYS Mineralys Therapeutics Inc750,000+0.0%$2024万0.9%
31RLAY Relay Therapeutics Inc1.1M+162.5%$1965万0.9%
32SGMT Sagimet Biosciences Inc2.5M+187.8%$1931万0.9%
33JBIO Jade Biosciences Inc840,350+31.3%$1867万0.8%
34COGT Cogent Biosciences Inc450,000−40.0%$1742万0.8%
35TVTX Travere Therapeutics Inc300,000+0.0%$1704万0.8%
36CGEM Cullinan Therapeutics Inc875,760+12.1%$1595万0.7%
37SVRA Savara Inc2.5M+0.0%$1547万0.7%
38IDYA Ideaya Biosciences Inc400,000—$1491万0.7%
39CATX Perspective Therapeutics Inc4.2M+33.2%$1437万0.6%
40ODTX Odyssey Therapeutics Inc766,346—$1434万0.6%
41HLXC Helix Acquisition Corp Iii1.2M+0.0%$1330万0.6%
42EQ Equillium Inc4.1M+234.3%$1312万0.6%
43ESTA Establishment Labs Hldgs Inc148,013+48.0%$1270万0.6%
44CLYM Climb Bio Inc972,000+38.9%$1267万0.6%
45TEVA Teva Pharmaceutical Inds Ltd374,000−73.3%$1267万0.6%
46MANE Veradermics Inc100,000+42.9%$1229万0.6%
47ARWR Arrowhead Pharmaceuticals In150,000−25.0%$1223万0.6%
48TSHA Taysha Gene Therapies Inc1.8M+75.0%$1192万0.5%
49DMRA Damora Therapeutics Inc425,000−5.6%$1105万0.5%
50EPRX Eupraxia Pharmaceuticals Inc1.6M+3.8%$1091万0.5%
來源:經 SEC EDGAR 的 Form 13F 申報。持倉截至 2026 年 6 月 30 日。期權(看漲/看跌)不計入股數。